CSIMarket
 


Revolution Medicines Inc   (RVMD)
Other Ticker:  
 
 

RVMD's Net Income Growth by Quarter and Year

Revolution Medicines Inc 's Net Income results by quarter and year




RVMD Net Income (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December - -52.68 -34.20 0.00
III Quarter September -73.33 -52.94 -27.22 0.00
II Quarter June -61.22 -44.30 -27.22 0.00
I Quarter March -57.65 -37.18 -21.74 0.00
FY   -192.20 -187.10 -110.38 0.00



RVMD Net Income third quarter 2022 Y/Y Growth Comment
Revolution Medicines Inc in the third quarter 2022 recorded net loss of $ -73.33 millions.

According to the results reported in the third quarter 2022, Revolution Medicines Inc achieved the best Net Income growth in Biotechnology & Pharmaceuticals industry. While Revolution Medicines Inc ' s Net Income no change of % ranks overall at the positon no. in the third quarter 2022.




RVMD Net Income ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Revolution Medicines Inc 's third quarter 2022 Net Income $ -73.33 millions RVMD's Income Statement
Revolution Medicines Inc 's third quarter 2021 Net Income $ -52.94 millions Quarterly RVMD's Income Statement
New: More RVMD's historic Net Income Growth >>


RVMD Net Income (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Net Income third quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Net Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Net Income third quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Net Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Net Income by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Revolution Medicines Inc 's Q/Q Net Income Growth


Net Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


RVMD's III. Quarter Q/Q Net Income Comment
III. Quarter 2022 accomplishment of -73.33 millions by Revolution Medicines Inc appear even less good considering the net loss -61.22 millions in the second quarter.

Within Biotechnology & Pharmaceuticals industry Revolution Medicines Inc achieved highest sequential Net Income growth. While Revolution Medicines Inc 's Net Income growth quarter on quarter, overall rank is .


Net Income Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Net Income Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Net Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


RVMD's III. Quarter Q/Q Net Income Comment
Current accomplishment of -73.33 millions by Revolution Medicines Inc appear even less good compare to the -61.22 millions a quarter before.

Within Biotechnology & Pharmaceuticals industry Revolution Medicines Inc achieved highest sequential Net Income growth. While Revolution Medicines Inc 's Net Income growth quarter on quarter, overall rank is .


Revolution Medicines Inc 's 12 Months Net Income Growth Year on Year


Net Income TTM Growth

12 Months Ending
(Sep 30 2022)
12 Months Ending
(Jun 30 2022)
12 Months Ending
(Mar 31 2022)
12 Months Ending
(Dec 31 2021)
12 Months Ending
(Sep 30 2021)
Cumulative Net Income 12 Months Ending $ -244.87 $ -224.49 $ -207.56 $ -187.09 $ -168.62
Y / Y Net Income Growth (TTM) - - - - -
Year on Year Net Income Growth Overall Ranking # # # # #
Seqeuential Net Income Change (TTM) - - - - -
Seq. Net Income Growth (TTM) Overall Ranking # # # # #




Cumulative Net Income growth Comment
Revolution Medicines Inc ' has realized cumulative trailing twelve months net loss of $ -245 millions in the Sep 30 2022 period.
The results are worsening as the cumulative net loss is becoming larger from $ -224.49 millions for the period from Jun 30 2022 to Sep 30 2021 and $ -61.22 millions from the TTM period ending Sep 30 2021 Soraia Silva Neves wrote.

Revolution Medicines Inc achieved highest trailing twelve month year on year Net Income growth. While overall Net Income growth ranking, remained unchanged compare to the previous quarter at no. .

Net Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Net Income TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Net Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Net Income growth Comment
Revolution Medicines Inc ' has realized cumulative trailing twelve months net loss of $ -245 millions in the Sep 30 2022 period.
The situation is worsening as the cumulative net loss is becoming larger from $ -224.49 millions in TTM ending quarter Jun 30 2022 and $ -61.22 millions from the TTM period ending Sep 30 2021.

Revolution Medicines Inc achieved highest trailing twelve month year on year Net Income growth. While overall Net Income growth ranking, remained unchanged compare to the previous quarter at no. .

Net Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Net Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Net Income Growth
Biotechnology & Pharmaceuticals Industry Net Income Growth Trends and Statistics
Healthcare Sector Net Income Growth Statistics
Net Income Growth Trends for overall market
RVMD's Net Income Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Net Income Growth
Lowest Ranking Net Income Growth
Net Income Growth for RVMD's Competitors
Net Income Growth for Revolution Medicines Inc 's Suppliers
Net Income Growth for RVMD's Customers

You may also want to know
RVMD's Annual Growth Rates RVMD's Profitability Ratios RVMD's Asset Turnover Ratio RVMD's Dividend Growth
RVMD's Roe RVMD's Valuation Ratios RVMD's Financial Strength Ratios RVMD's Dividend Payout Ratio
RVMD's Roa RVMD's Inventory Turnover Ratio RVMD's Growth Rates RVMD's Dividend Comparisons



Companies with similar Net Income no change for the quarter ending Sep 30 2022 within Healthcare SectorY/Y Change %Net Income for the quarter ending Sep 30 2022
Vir Biotechnology Inc 58.76%$ 58.757 millions
United Therapeutics Corporation47.08%$ 47.081 millions
Dexcom Inc 42.74%$ 42.736 millions
Medpace Holdings Inc 35.93%$ 35.931 millions
Zimmer Biomet Holdings Inc 33.20%$ 33.196 millions
Iradimed Corporation33.03%$ 33.026 millions
Eli Lilly And Company30.77%$ 30.772 millions
Bio techne Corp30.09%$ 30.085 millions
Merit Medical Systems Inc27.62%$ 27.618 millions
Abbvie Inc 24.28%$ 24.277 millions
Repligen Corp20.62%$ 20.619 millions


Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

BIXT's Profile

Stock Price

BIXT's Financials

Business Description

Fundamentals

Charts & Quotes

BIXT's News

Suppliers

BIXT's Competitors

Customers & Markets

Economic Indicators

BIXT's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071